losartan has been researched along with pyruvic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Butorov, IV; Butorov, SI | 1 |
| de Cavanagh, EM; Ferder, L; Fraga, CG; Inserra, F; Piotrkowski, B; Stella, I; Toblli, JE | 1 |
2 other study(ies) available for losartan and pyruvic acid
| Article | Year |
|---|---|
[Use of lozartan in patients with chronic cor pulmonale].
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Gas Analysis; Chronic Disease; Erythrocytes; Glucosephosphate Dehydrogenase; Humans; Losartan; Middle Aged; Oxidation-Reduction; Phagocytosis; Pulmonary Heart Disease; Pyruvic Acid; Treatment Outcome | 2005 |
Renal mitochondrial impairment is attenuated by AT1 blockade in experimental Type I diabetes.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Antioxidants; Blood Glucose; Blood Pressure; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Electron Transport Complex IV; Glutathione; Hydrogen Peroxide; Ion Channels; Kidney; Losartan; Male; Membrane Potential, Mitochondrial; Mitochondria; Mitochondrial Proteins; Nitric Oxide Synthase; Pyruvic Acid; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Uncoupling Protein 2 | 2008 |